Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 12:30 save search
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
STIM | $3.8 -0.78% -0.79% 49K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
TENX | $3.62 -1.63% -1.66% 14K
|
Health Technology
|
| O: 7.89%
H: 1.95%
C: -2.93%
first levosimendan treatment ongoing for therapeutics potential
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
LSTA | $2.85 -5.82% 2K
|
Manufacturing
|
| O: 0.34%
H: 9.62%
C: 3.78%
fda drug granted treatment designation for therapeutics
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 0.57%
H: 7.01%
C: 3.79%
nrx-101 depression treatment pharmaceuticals trial
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
Published: 2024-04-02 (Crawled : 12:30) - prnewswire.com
TCBP | $1.475 3.87% 3.73% 84K
|
| Email alert
Add to watchlist
capacity treatment
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
Published: 2024-03-28 (Crawled : 12:30) - prnewswire.com
PTCT | News S | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: 0.14%
H: 1.19%
C: -1.32%
treatment ema submission
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
Published: 2024-03-25 (Crawled : 12:30) - globenewswire.com
STIM | $3.8 -0.78% -0.79% 49K
|
Health Technology
|
| O: 13.48%
H: 3.96%
C: -1.88%
neurostar fda depression treatment clearance advanced therapy
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
Published: 2024-03-21 (Crawled : 12:30) - globenewswire.com
CHRO | $1.5 22.45% 2.67% 120K
|
n/a
|
| O: 3.14%
H: 1.36%
C: -5.76%
treatment eye program simon
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 1.55%
H: 19.85%
C: 18.32%
breast update cancer treatment program therapeutics
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
Published: 2024-03-19 (Crawled : 12:30) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.33%
H: 1.89%
C: 0.64%
drug health genetic als review treatment canada submission
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Published: 2024-03-18 (Crawled : 12:30) - prnewswire.com
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: -2.23%
H: 11.11%
C: 0.03%
fda t-cell resubmission treatment pharmaceuticals
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Published: 2024-03-18 (Crawled : 12:30) - globenewswire.com
DERM | $3.45 -3.63% -3.77% 100K
|
|
| O: 2.94%
H: 14.57%
C: 6.86%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 3.36%
H: 0.5%
C: -4.0%
dfd-29 fda drug corporation treatment medical application
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
RZLT 4 | $3.44 4.24% 4.07% 340K
|
Technology Services
|
| O: 3.93%
H: 5.41%
C: -2.97%
rz358 cell treatment hypoglycemia tumor potential
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
CGTX | $1.86 1.09% 1.08% 120K
|
|
| O: -1.9%
H: 1.94%
C: -0.97%
ct1812 disease alzheimer’s treatment therapeutics
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
Published: 2024-03-04 (Crawled : 12:30) - globenewswire.com
ZVRA | $4.515 0.33% 0.33% 360K
|
n/a
|
| O: -5.79%
H: 0.15%
C: -6.75%
fda disease update treatment pdufa therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2024-03-01 (Crawled : 12:30) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 1.86%
H: 4.79%
C: 2.39%
briumvi presentation sclerosis treatment research therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.